Adults with persistent acne can ask a dermatologist about clascoterone 1% cream (Winlevi), a prescription topical that targets androgen signals in skin. They can also ask where it fits with standard topicals, what compounded topical spironolactone offers, and when systemic hormonal options merit discussion. Topical hormonal care means medicine put on skin to reduce local effects of androgens, skin-oil triggers, rather than changing hormone levels through the body. Persistent acne in adults often needs personal advice, so bring cycle patterns, products, and prior treatments to the visit.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How does clascoterone act on acne?
- What side effects should you discuss?
- What can topical spironolactone offer?
- What history helps tailor your visit?
How does clascoterone act on acne?
Clascoterone 1% cream (Winlevi) is a first-in-class topical androgen-receptor inhibitor. Drugs.com lists its FDA approval on Aug. 26, 2020 for acne vulgaris in patients 12 years and older in its approval history. DermNet explains it competes with dihydrotestosterone for androgen receptors in sebaceous glands and hair follicles in its clascoterone overview.
That local block helps lower excess sebum and inflammation without altering systemic hormone levels. Ask whether oil-prone zones like chin, jaw, and forehead fit this action. The American Academy of Dermatology 2024 acne guidelines strongly recommend benzoyl peroxide, topical retinoids and fixed-dose combinations, and conditionally recommend topical clascoterone. Ask where clascoterone fits for you: alone, added to a retinoid, or instead of another topical.
What side effects should you discuss?
DailyMed labeling warns of local irritation with itching, burning, redness or peeling in the Winlevi label record. Ask how to space moisturizer, cleanser, and other actives to limit irritation. Ask when redness or peeling should prompt a call.
DailyMed also notes hypothalamic-pituitary-adrenal axis suppression, seen in 5% of adults and 9% of adolescents at day 14 with recovery after stopping. That risk is uncommon and reversible in the label data. Ask what signs warrant review, especially with broad use in teens.
What can topical spironolactone offer?
Miiskin's clinical summary states compounded topical spironolactone has no FDA finding of safety or efficacy for acne. It also has not been shown equivalent to oral spironolactone, so use rests on prescriber judgment. Ask your dermatologist why a compounded formula is or is not right for you.
A 2026 narrative review indexed on PubMed describes evidence for topical spironolactone as limited to small heterogeneous trials. The same review calls oral spironolactone robust for adult female acne, while topical appears promising only for mild-to-moderate disease. Ask what severity you have and what success would look like.
What history helps tailor your visit?
A Springer Medicine summary of Williams et al. estimates facial acne in 14% of women ages 26-44, often with premenstrual flares. Persistent adult acne commonly affects women.
Bring notes on cycle timing, breakouts, and scarring. An NIH/PMC hormonal therapies update lists three combined oral contraceptives FDA-approved for moderate-to-severe acne in females seeking contraception: Ortho Tri-Cyclen, Estrostep Fe and Yaz. Ask whether a systemic option fits alongside topicals. Bring this short history to save time:.
- cycle dates and premenstrual flares
- all topicals, cosmetics, and hair products
- signs like excess hair growth or irregular periods
- prior prescriptions, irritation, and scar or dark-mark history
You Might Also Like
- Why the 2026 Acne Diet Review Warns Against Restrictive Regimens: Questions Adults With Persistent Acne Can Ask a Dermatologist
- Limited Topical Spironolactone Evidence in the 2026 Review: Study Design and Evidence Limits for Adults With Persistent Acne
- Adult Female Acne Antiandrogen Treatments in a 2026 Review: Study Design and Evidence Limits for Adults With Persistent Acne